BioCentury
ARTICLE | Company News

Isis Pharmaceuticals, AstraZeneca deal

November 17, 2014 8:00 AM UTC

The companies partnered to develop new targeted delivery methods for antisense oligonucleotides with a focus on cancer and cardiovascular and metabolic diseases. Each company will provide funding and investigators and share rights to the results. The collaborators will research delivery technologies for new therapeutics as well as the four previously partnered oligonucleotides including AZD9150 ( ISIS-STAT3Rx) and AZD5312 ( ISIS-ARRx). AZD9150 is an antisense inhibitor of signal transducer and activator of transcription 3 (STAT3) in Phase I/IIa testing to treat hepatocellular carcinoma (HCC) and AZD5312 is an antisense inhibitor of the production of androgen receptor in Phase I testing to treat solid tumors. Both companies declined to discuss financial terms. ...